Ovarian and pancreatic cancers had the highest proportions of patients exhibiting both high CD40 and low-moderate CD40L expression—33% (14/43) and 24% (13/55), respectively—representing the only two malignancies in which more than 20% of patients had this expression profile (Fig. 3B). This evidence concerns the gene CD40 and familial pancreatic carcinoma.